PURPOSE: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality
from bone marrow failure or transformation to acute leukemia. Supportive care is standard …

Purpose Within the last two decades, a new understanding of the biology of myelodysplastic
syndrome (MDS) has developed. With this understanding, new classification systems, such …

BACKGROUND: Azacitidine induces responses and prolongs overall survival compared
with conventional care regimens in patients who have high‐risk myelodysplastic syndromes …

PURPOSE: The impact of azacytidine (Aza C) on the quality of life of 191 patients with
myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial …

Background Drug treatments for patients with high-risk myelodysplastic syndromes provide
no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall …

The phase III AZA-001 study established that azacitidine significantly improves overall
survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence …

Purpose: This article summarizes data submitted to the US Food and Drug Administration for
marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation …

Purpose Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a
dosing schedule of 75 mg/m2/d subcutaneously for 7 days every 4 weeks. The initial phase …

In the phase III AZA‐001 trial, low‐dose cytarabine (LDara‐C), the most widely used low‐
dose chemotherapy in patients with higher‐risk myelodysplastic syndrome (MDS) who are …

BACKGROUND: In the AZA‐001 trial, azacitidine (75 mg/m2/d subcutaneously for Days 1‐7
of every 28‐day cycle) demonstrated improved survival compared with conventional care …